预约演示
更新于：2025-02-19
Ibuprofen Lysine
布洛芬赖氨酸
更新于：2025-02-19
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H32N2O4 |
InChIKeyIHHXIUAEPKVVII-ZSCHJXSPSA-N |
CAS号57469-77-9 |
关联
10
项与 布洛芬赖氨酸 相关的临床试验NCT05340582
Co-administration of Acetaminophen with Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants - the ACEDUCT Trial
IRCT20140527017880N8
Comparative evaluation of the effect of ibuprofen lysine & gelofen - acetaminophen on postoperative endodontic dental pain with irreversible pulpaitis
IRCT20130812014333N131
comparison of the effect of ibuprofen lysine with gelofen-acetaminophen on postoperative pain of mandibular third molars surgery
100 项与 布洛芬赖氨酸 相关的临床结果
登录后查看更多信息
100 项与 布洛芬赖氨酸 相关的转化医学
登录后查看更多信息
100 项与 布洛芬赖氨酸 相关的专利（医药）
登录后查看更多信息
24,954
项与 布洛芬赖氨酸 相关的文献（医药）2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
Enhanced protein-bound uremic toxin clearance by a membrane-drug-dendrimer synergic system
作者: Faria, Monica ; Pires, Rita F. ; Almeida, Pedro ; Macedo, Ana ; Brilhante, Dialina ; Bonifacio, Vasco D. B.
Challenges in effectively removing protein-bound uremic toxins (PBUTs), are a significant concern for patients with end stage renal disease (ESRD) undergoing hemodialysis (HD).Conventional 4-h HD treatments rely on the transport of small and middle mols. through the semipermeable membranes of the hemodialyzer, moving from the blood side to the dialyzate compartment.PBUTs, however, circulate bound to human serum albumin (HSA), forming large toxin-protein complexes that cannot cross these membranes.In recent years, the use of pharmaceutical drugs with competitive binding properties has emerged as a promising solutionA 2019 clin. trial demonstrated the potential of enhancing indoxyl sulfate (IS) removal - a key PBUT - by injecting 800 mg of ibuprofen (IBU) over 19 min during the initial phase of HD.Although this increased IS clearance by 2.4-fold, the effect diminished rapidly, returning to pre-infusion levels between 60 and 240 min.Addnl., residual IBU was detected in patients, raising safety concerns and highlighting the unsustainability of this approach.In response, we developed a method for the slow, controlled release of lower doses of IBU throughout the entire HD session using polymeric nanocarriers known for their high drug-loading capacity and controlled release properties.A lab-scale extracorporeal blood circulation circuit was constructed, where IBU (<8 mg) was gradually released into the blood plasma line using fourth-generation polyurea dendrimers (IBU@PUREG4).The concentration of free IS was monitored over a 4-h period, and a membrane module that retains HSA while permeating unbound IS was positioned downstream from the IBU@PUREG4 release site.Our results showed a 3.7-fold increase in the unbound IS concentration in blood plasma and a 3.8-fold increase in IS clearance, validating the displacement effect of controlled low-dose IBU release.This innovative approach not only improves the efficiency of PBUT removal but also reduces the risk of excessive accumulation of competitive binders, such as IBU, in patients undergoing regular HD, making it a safer long-term solution for ESRD management.
2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
Defective NH2-MIL-53(Fe) with highly exposed metal active centers for enhanced synergistic adsorption and photocatalysis of ibuprofen
作者: Liu, Yongdi ; Duan, Jun ; Sun, Xianbo ; Song, Yanyu ; Liu, Wen ; Cai, Zhengqing ; Nghiem, Long D.
Since adsorption is a prerequisite for photocatalytic surface reactions, it is attractive to study adsorption and photocatalysis as a synergistic technique to achieve efficient decontamination.In this study, defective NH2-MIL-53(Fe) with highly exposed metal active centers was prepared through ligand modification and defect engineering, which exhibits dramatically enhanced adsorption and photocatalysis activity compared with the original MIL-53(Fe).With ibuprofen (IBP) as the target pollutant, the adsorption capacity increases from 11.4 to 25.0 mg/g within 60 min, and the photocatalysis rate under simulated solar light increases from 0.0044 to 0.056 min-1.For adsorption, -NH2 groups improves the adsorption affinity of the catalyst through addnl. hydrogen bonding effect and acid-base interaction.With HCl as modulator, defect construction ensures full exposure of metal active centers, and the exposed metal clusters become new adsorption sites for IBP through hydrogen bonding interaction.Moreover, by inducing increased free pore volume, defect engineering enhances the sp. surface area of the material, thus allowing sufficient contact between the material and IBP to improve the adsorption capacity.For photocatalysis, -NH2 groups provide lone pair nitrogen to increase the electron d. of benzene rings, thus promoting the electron transfer from ligands to metal clusters.Simultaneously, -NH2 substitution narrows the bandgap of catalyst by regulating the electronic structure, and narrower bandgap improves the visible light response of the material.As active sites for photocatalysis, highly exposed Fe-O clusters become more accessible due to defect construction, which can be directly excited by visible light to produce photoinduced carriers.The quenching experiments demonstrate that h+ and •O-2 play the dominant role for photolysis, and the ecol. toxicity of IBP is significantly reduced through the photocatalysis process.This work provides valuable reference for the research of bifunctional catalysts with synergistic adsorption and photocatalytic oxidation ability.
2025-05-01SEPARATION AND PURIFICATION TECHNOLOGY
Removal of emerging contaminants from water using novel electroconductive membranes in a hybrid membrane distillation and electro-Fenton process
作者: Omi, Farah Rahman ; Wishart, David ; Dilokekunakul, Waralee ; Wessling, Matthias ; Sadrzadeh, Mohtada ; Rahman Omi, Farah ; Singh, Upasana ; Davis Vecitis, Chad ; Mohseni, Mojtaba ; Rastgar, Masoud ; Keller, Robert
The treatment of emerging contaminants (ECs) with extremely low concentrations presents a significant challenge in advanced oxidation processes (AOPs) like electro-Fenton (EF).Combining EF with membrane distillation (MD) can concentrate the feed solution, thereby improving the reaction kinetics.Our innovation integrates MD with EF using a hydrophobic, elec. conductive membrane, offering a sustainable solution for continuous dewatering while simultaneously facilitating the EF reaction.The electroactive membrane, fabricated via a simple "spray and cure" method with Ag ink on polytetrafluoroethylene (PTFE) membrane, exhibited high elec. conductivity (60000 S/cm) and underwater oleophobicity.The hybrid EF-MD showed a 2.5-fold increase in methyl orange (MO) degradation and a 3.4-fold reduction in the total organic carbon (TOC) compared to EF alone at room temperatureTesting ibuprofen removal at 350 ppb, EF-MD achieved 81 % degradation within a 2-h operation time in a temperature range of 20-60 °C.In comparison, EF alone required over 6 h at 60 °C to achieve a similar level of ibuprofen degradationThe fabricated Ag-PTFE membrane can be operated at low elec. potential (-1 V), maintaining a steady state of 10 mA current, making it an energy-efficient technol. for EC removal.Moreover, it shows exceptional antibiofouling characteristics as it completely deactivates E. coli by > 99 % at 1 V.The Ag-PTFE membrane can be fabricated at larger scales and can actively capture and degrade harmful micropollutants that are often resistant to conventional treatment methods.This results in cleaner, safer water for both consumption and environmental discharge.
100 项与 布洛芬赖氨酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉导管未闭 | 美国 | 2006-04-13 | |
| 关节炎 | 澳大利亚 | 2003-08-12 | |
| 背痛 | 澳大利亚 | 2003-08-12 | |
| 痛经 | 澳大利亚 | 2003-08-12 | |
| 头痛 | 澳大利亚 | 2003-08-12 | |
| 偏头痛 | 澳大利亚 | 2003-08-12 | |
| 肌肉骨骼疼痛 | 澳大利亚 | 2003-08-12 | |
| 紧张型头痛 | 澳大利亚 | 2003-08-12 | |
| 牙痛 | 澳大利亚 | 2003-08-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用